Detalhe da pesquisa
1.
Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
J Drugs Dermatol
; 18(10): 1059-1060, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31603636
2.
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
J Am Acad Dermatol
; 78(1): 70-80, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29102053
3.
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
J Am Acad Dermatol
; 77(5): 845-854.e5, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28893407
4.
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
J Drugs Dermatol
; 16(10): 1002-1013, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29036254
5.
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
J Am Acad Dermatol
; 74(5): 851-61.e4, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26853180
6.
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
J Am Acad Dermatol
; 2015 Jan 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25582533
7.
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
J Drugs Dermatol
; 14(7): 706-14, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26151787
8.
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
J Drugs Dermatol
; 13(12): 1441-8, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25607786
9.
Considerations for the US health-system pharmacist in a world of biosimilars.
Drugs Context
; 92020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32158487
10.
Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
J Dermatolog Treat
; 30(6): 534-539, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29619848
11.
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.
Biologics
; 12: 127-134, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30498332
12.
A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population.
Biologics
; 12: 97-106, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30323555
13.
Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade®.
BioDrugs
; 32(5): 405-414, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30143982
14.
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
JAMA Dermatol
; 151(9): 961-9, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25970800
15.
Comment on: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes".
Drugs
; 78(8): 851-852, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29785562
16.
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Ann N Y Acad Sci
; 1263: 1-12, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22823582
17.
Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature.
Arch Dermatol
; 147(10): 1197-202, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21680761
18.
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Ann N Y Acad Sci
; 1222: 30-9, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21434940